Abstract
The room temperature liquid metal gallium, as a multi-targeted pharmacologically active metallic element with long historical investigation, has shown great potential in the field of medicine, especially in antibacterial, anti-inflammatory, anticancer, osteogenesis, radio-pharmacology, molecular imaging and more emerging drug categories. However, diverse structures and physical/chemical compositions, complex interactions with living organisms, and insufficient mechanism interpretation, pose serious challenges for the clinical translation of gallium-based pharmaceuticals. This review systematically identified and described promising gallium-based pharmaceuticals, with emphasis on typical features, fundamental pharmaceutical activities, representative pharmaceutical formulations, and practical implementations, aiming to inspire innovative concepts for drug discovery and further investigation. Meaningfully, new insights into gallium-based liquid metals for screening pharmaceutical formulations are presented, which promise to bring broader strategies for enhancing the bioavailability, targetability, biocompatibility and pharmacological efficacy of active pharmaceutical ingredients (Ga(0)/Ga(III)). Besides, the unresolved challenges and future perspectives of these emerging gallium-based pharmaceuticals were also outlined, aiming to aid for future academic explorations and translational medicine of gallium-based pharmaceuticals. Overall, gallium-based pharmaceuticals with tremendous pharmaceutical formulations and pharmaceutical activities open up a huge scope great potential for future pharmaceutical engineering, which are promising to usher epochal metallodrug development with a series of breakthrough discoveries and pioneering technologies.
Introduction
While platinum-based drugs like cisplatin have dominated chemotherapy for decades, they often come with high toxicity and resistance issues. Gallium has been studied since the 1930s as a safer alternative, but its clinical progress was historically hampered by poor bioavailability and complex interactions with living tissues. Recent breakthroughs in material science are bridging this gap, transforming gallium from simple salts into sophisticated "smart" materials—specifically liquid metal (LM) nanopharmaceuticals—that can be engineered to respond to external stimuli like light, magnets, or ultrasound.
The Evolution of Gallium Pharmaceuticals
The development of gallium-based medicine has progressed through three distinct generations, moving from simple chemical compounds to complex, responsive systems:
- First Generation: Simple Ga(III) salts, such as gallium nitrate, primarily used for treating hypercalcemia.
- Second Generation: Organic Ga(III) complexes (e.g., GaM, KP46) designed to prevent hydrolysis and improve oral absorption.
- Third Generation: Gallium-based nanomedicines and Liquid Metals (LMs) that utilize the unique physical properties of Ga(0).
Mechanisms of Action: The "Trojan Horse" Strategy
The core pharmacological advantage of gallium lies in its chemical similarity to ferric iron (Fe³⁺). Their ionic radii are nearly identical (0.62 Å vs 0.645 Å), allowing Ga³⁺ to hijack iron transport systems and enter cells undetected—a "Trojan Horse" strategy. Once inside, gallium disrupts metabolic machinery because, unlike iron, it is redox-inert in biological settings and cannot switch oxidation states. This effectively starves bacteria and cancer cells of functional iron.
Beyond chemical mimicry, liquid metal gallium introduces mechanical and physical pathways for therapy. LMs can act as "energy sensitizers," converting near-infrared light into heat (photothermal therapy) or using ultrasound to trigger drug release. Furthermore, they can physically disrupt bacterial biofilms or cell membranes through shape transformation and envelope stress.
Key Therapeutic Insights
- Anticancer Efficacy: Second-generation complexes like KP46 show potent activity against lung and breast cancers with IC₅₀ values as low as 1–3 μM. Gallium-transferrin conjugates have even shown the ability to reduce doxorubicin resistance by ~100-fold by bypassing efflux pumps.
- Antibacterial Power: Gallium-based LMs demonstrate superior activity against "superbugs" like MRSA and P. aeruginosa by disrupting iron metabolism and generating reactive oxygen species (ROS).
- Dual-Action Bone Therapy: Gallium is uniquely "pro-bone," simultaneously inhibiting osteoclasts (cells that break down bone) and promoting osteoblasts (cells that build bone), offering a dual-threat treatment for osteoporosis and bone cancer.
- Molecular Imaging: ⁶⁸Ga-labeled pharmaceuticals are already FDA-approved for PET imaging, providing high-contrast visualization of neuroendocrine tumors.
Future Perspectives and Challenges
Despite its potential, several hurdles remain for the clinical translation of liquid metal gallium:
- Long-term Biosafety: Rigorous "cradle-to-grave" toxicological studies are needed to determine the eventual fate of residual liquid metal droplets in the body.
- Pharmacokinetics: Standardized data on how these nanocarriers circulate, accumulate, and clear from different organs is currently lacking.
- Regulatory Hurdles: The diverse physical and chemical compositions of LMs make establishing standardized manufacturing and quality control protocols difficult for regulatory approval.
In conclusion, gallium-based pharmaceuticals represent a promising frontier in metallodrug development, offering a unique blend of chemical mimicry and mechanical action to address some of the most challenging diseases in modern medicine.
Summary updated